• Explore /
  • Poster
  • / Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers.

Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers.

Abstract Poster

Authors

Koosha Paydary

Koosha Paydary

University of Chicago Medical Center, Chicago, IL

Koosha Paydary , Aurelie Desgardin , Chih-Yi Liao , Ardaman Shergill , Natalie Marie Reizine , Stephanie Moya , Bryan Peterson , Katherine Reyes , Chanelle Robinzine , Belen Martinez-Caro Aguado , Christine Racette , Elena Ignatiev , Anu Radha Neerukonda , Yuan Ji , Blase N. Polite , Daniel V.T. Catenacci

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04361708

DOI

10.1200/JCO.2022.40.4_suppl.316

Abstract #

316

Poster Bd #

G2

Abstract Disclosures

Similar Posters

Poster

2014 Gastrointestinal Cancers Symposium

FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study.

FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study.

First Author: Howard Safran

First Author: Daniel Brungs

First Author: Scott Kopetz

First Author: Manish Sharma